Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

US11161854B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• David A. Candito · Wrentham, US
• Thomas H. Graham · Somerville, US
• John J. Acton, III · Cranford, US
• Ryan Chau · Somerville, US
• Joanna L. Chen · Braintree, US
• J. Michael Ellis · Needham, US
• Peter H. Fuller · Ashland, US
• Anmol Gulati · Watertown, US
• Hakan Gunaydin · Boston, US
• Solomon D. Kattar · Arlington, US
• Mitchell H. Keylor · Malden, US
• Blair T. Lapointe · Brookline, US
• Ping Liu · Shanghai, CN
• Weiguo Liu · San Leandro, US
• Joey L. Methot · Westwood, US
• Santhosh F. Neelamkavil · Edison, US
• Vladimir Simov · Boston, US
• Ling Tong · Hackettstown, US
• Harold B. Wood · Westfield, US

Key dates

• Filing date: Oct 8, 2018
• Grant date: Nov 2, 2021
• Expiry date: Nov 4, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.